volume 2, issue 8, PS483 2007
DOI: 10.1097/01.jto.0000283445.47949.8a
View full text
|
|
Share

Abstract: Background: Non-small-cell lung cancer (NSCLC) is the most common cancer in the world and prognosis is poor. Recently, erlotinib, an epithelial growth factor receptor (EGF-R) tyrosine kinase inhibitor has shown to be effective in terms of survival in second/third-line chemotherapy. However, the overall response rate is about 9%.

Search citation statements

Order By: Relevance

Citation Types

0
0
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals